Novogen Limited announced a joint venture with Yale University dedicated to developing personalized approaches to chemotherapy to fight ovarian cancer.
The joint venture will be known as CanTx.
Novogen will own 85% of the new company and Novogen CEO Graham Kelly, PhD will be CEOoft the new joint venture as well.
The CanTx Board will be comprised of directors representing both Novogen and Yale.
CanTx will assume responsibility for advancing Novogen's super-benzopyran drug technology into the clinic for the treatment of ovarian cancer.
Novogen retains full ownership of its drug technology intellectual property and will grant CanTx access to that IP for drug development purposes.
Novogen will continue to explore applications of the same technology platform in a range of other clinical indications including glioblastoma, along with its anti-tropomyosin drug technology in the areas of prostate cancer, melanoma and neuroblastoma.